Uterus Transplants Enable Pregnancy and Birth for Women Without a Womb

For women born without a uterus or who have lost theirs to medical necessity, the dream of biological parenthood has long seemed unattainable. Yet in 2026, a decade of surgical innovation has transformed this reality. At Baylor University Medical Center—the world’s largest uterus transplant program—33 women have received transplanted wombs, with 27 delivering healthy babies. The procedure now stands at the threshold of becoming a standard fertility option, but critical questions remain: Who will benefit most? What risks persist? And where can patients access this cutting-edge care?

Key Clinical Takeaways:

• Uterus transplants now enable pregnancy for women with absolute uterine factor infertility (AUFI), with 27 live births reported at Baylor since 2016.
• Complications mirror natural pregnancy risks—gestational diabetes and hypertension are the most common—but long-term data on transplant rejection and uterine function remain limited.
• Access hinges on donor availability and specialized centers; fewer than 50 global programs exist, with most in the U.S. And Europe.

The Clinical Milestone: From First Births to a Growing Case Series

The journey began in 2014, when Sweden’s Sahlgrenska University Hospital achieved the first live birth after uterus transplantation. Three years later, Baylor University Medical Center in Dallas reported the first U.S. Birth, marking a pivotal shift from experimental surgery to viable clinical practice. By April 2026, Baylor’s program—funded through a combination of institutional grants and philanthropic support—had performed 44 transplants, with 37 achieving functional graft integration within a month of surgery.

Of those 37, 33 underwent embryo transfer, resulting in 31 pregnancies and 27 live births. The data, published in the Journal of the American Medical Association (JAMA) on May 1, 2026, represent the largest case series to date. Eight women experienced pregnancy-related complications—primarily gestational diabetes (5 cases) and hypertensive disorders (3 cases)—consistent with rates observed in the general population. No transplant-specific complications (e.g., graft rejection leading to pregnancy loss) were reported in this cohort.

“This isn’t just about delivering a baby—it’s about restoring the physiological experience of pregnancy, which carries profound psychological and emotional benefits.”

Biological Mechanisms and Surgical Innovation

The procedure itself is a high-stakes orchestration of vascular and pelvic surgery. A donated uterus—typically from a living relative to minimize immunological mismatch—is transplanted via anastomosis to the recipient’s iliac arteries and veins, with the cervix sutured to the vaginal canal. Unlike kidney or liver transplants, the uterus lacks lymphatic drainage, creating a unique immunological challenge: chronic rejection remains the primary long-term risk, though immunosuppressive regimens (tacrolimus, mycophenolate mofetil) have reduced acute rejection rates to <5% in the Baylor cohort.

Yet the biological hurdles extend beyond surgery. The endometrium—the uterine lining—must achieve receptivity for embryo implantation, a process influenced by hormonal priming and potential immune-mediated scarring. A 2025 study in Nature Communications ([link]) identified a 12% incidence of endometrial dysfunction post-transplant, though this did not correlate with pregnancy outcomes in the Baylor series. Researchers are now exploring in utero conditioning protocols to mitigate this risk.

Public Health Implications: Who Benefits, and at What Cost?

Absolute uterine factor infertility (AUFI) affects approximately 1 in 500 women globally, encompassing congenital conditions like Mayer-Rokitansky-Küster-Hauser (MRKH) syndrome and acquired causes such as hysterectomy for cancer or severe endometriosis. While uterus transplantation offers a solution, it is not without ethical and logistical constraints. The procedure requires lifelong immunosuppression, exposing recipients to infections (e.g., BK virus, CMV) and malignancies (lymphoma risk increases by 3–5% over 10 years per Transplantation data [2023]).

Cost is another barrier. At Baylor, the procedure averages $250,000 per transplant, excluding post-surgical care. Insurance coverage remains patchwork; only 12 U.S. States mandate partial reimbursement for fertility treatments, and none currently specify uterus transplants. The American Society of Reproductive Medicine (ASRM) has classified the procedure as “experimental” until long-term data on graft survival and maternal-fetal outcomes exceed 10 years—a threshold likely to be met by 2030.

“We’re at a crossroads. The data show safety and efficacy, but scalability depends on addressing donor shortages and equitable access. Right now, this is a privilege, not a right.”

Directory Triage: Where to Turn for Care

For patients evaluating uterus transplantation, the first step is consulting a board-certified reproductive endocrinologist affiliated with a transplant center. Baylor remains the global leader, but emerging programs include:

• Cleveland Clinic’s Center for Reproductive Medicine, which began its pilot program in 2025 and has achieved a 70% graft survival rate in early cases.
• Johns Hopkins Medicine, where a multidisciplinary team is developing protocols for living donor transplants to reduce waitlist times.
• Healthcare compliance attorneys specializing in fertility law, who can navigate the complex landscape of insurance denials and experimental treatment exclusions.

For healthcare providers seeking to integrate uterus transplantation into practice, the ASRM’s Uterus Transplant Task Force offers credentialing pathways, while the International Society for Uterus Transplantation (ISUT) provides standardized surgical training modules.

The Future: Toward a New Standard of Care?

The next frontier lies in reducing immunosuppression dependence. Research at the Karolinska Institute is testing tolerogenic dendritic cell therapy to induce immune tolerance, potentially eliminating chronic rejection risks. Concurrently, bioengineered uteri—grown from patient-derived stem cells—could eliminate donor shortages entirely, though clinical trials remain years away.

For now, uterus transplantation occupies a liminal space: a proven but not yet routine option. Its trajectory mirrors that of other once-niche procedures, from in vitro fertilization to lung transplants. The question is no longer if it will become standard practice, but when—and for whom. As Dr. Johannesson notes, “The goal isn’t just to deliver a baby. It’s to deliver a future.”

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.